Roche’s TIG­IT drug tiragolum­ab flunks an­oth­er Phase 3 lung can­cer test

Roche will halt a late-stage study of tiragolum­ab af­ter it failed to help cer­tain lung can­cer pa­tients, adding to a string of reg­is­tra­tional dis­ap­point­ments for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER